(Q39374983)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23902240%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23902240%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23902240%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Rossella Elisei

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23902240%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Virginia Cappagli

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23902240%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

language of work or name

English

0 references

publication date

1 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23902240%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23902240%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23902240%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23902240%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

1083-1092

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23902240%20AND%20SRC:MED&resulttype=core&format=json

Medullary thyroid cancer: management guidelines of the American Thyroid Association

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Sorafenib therapy decreases the clearance of thyrotropin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.128

21 January 2018

Identifiers

DOI

10.2217/FON.13.128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23902240%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference